Ausgabe 5/2011
Inhalt (48 Artikel)
Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO
Steven Hutchens, Yefim Manevich, Lin He, Kenneth D. Tew, Danyelle M. Townsend
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity
Jérôme Devy, Farid Ouchani, Christelle Oudot, Jean Jacques Helesbeux, Enguerran Vanquelef, Stéphanie Salesse, Fanja Rabenoelina, Siana Al-Khara, Isabelle Letinois, Olivier Duval, Laurent Martiny, Emmanuelle Charpentier
In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes
Georgi Momekov, Margarita Karaivanova, Iva Ugrinova, Evdokia Pasheva, Galina Gencheva, Daniela Tsekova, Sonia Arpadjan, Panayot R. Bontchev
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
Norma O’Donovan, Annette T. Byrne, Aisling E. O’Connor, Sharon McGee, William M. Gallagher, John Crown
An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities
Julio Benites, Jaime A. Valderrama, Henryk Taper, Pedro Buc Calderon
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
Roos L. Oostendorp, T. Buckle, G. Lambert, J. S. Garrigue, J. H. Beijnen, J. H. M. Schellens, O. van Tellingen
A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis
Esther A. Guzmán, Jacob D. Johnson, Patricia A. Linley, Sarath E. Gunasekera, Amy E. Wright
5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis
Danqing Xu, Ji Cao, Shijing Qian, Lin Li, Chunqi Hu, Qinjie Weng, Jianshu Lou, Difeng Zhu, Hong Zhu, Yongzhou Hu, Qiaojun He, Bo Yang
D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα
Min Gui, Da-Kuo Shi, Min Huang, Yu Zhao, Qi-Ming Sun, Jing Zhang, Qin Chen, Jian-Ming Feng, Chun-Hong Liu, Ming Li, Ying-Xia Li, MeiYu Geng, Jian Ding
The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity
Pere Tubert, Montserrat Rodríguez, Marc Ribó, Antoni Benito, Maria Vilanova
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
Alfonso Quintás-Cardama, Taghi Manshouri, Zeev Estrov, David Harris, Ying Zhang, Amos Gaikwad, Hagop M. Kantarjian, Srdan Verstovsek
Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line
Yukako Fukushi, Masaharu Hazawa, Kenji Takahashi, Atsushi Yoshizawa, Ikuo Kashiwakura
Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain
Meaghan MacPhee, Zakaria Rachid, Margarita Todorova, Qiyu Qiu, Gina Belinsky, Bertrand J. Jean-Claude
MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis
Piotr Jasinski, Pawel Zwolak, Rachel Isaksson Vogel, Vidya Bodempudi, Kaoru Terai, Jorge Galvez, David Land, Arkadiusz Z. Dudek
NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells
Bo-Kyung Kim, Dong-Myung Kim, Kyung-Sook Chung, Song-Kyu Park, Shin-Jung Choi, Alexander Song, Kiho Lee, Chang-Woo Lee, Kyung-Bin Song, Gyoonhee Han, Julian Simon, Hwan Mook Kim, Misun Won
A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice
Jin-Bin Jia, Wen-Quan Wang, Hui-Chuan Sun, Liang Liu, Xiao-Dong Zhu, Ling-Qun Kong, Zong-Tao Chai, Wei Zhang, Ju-Bo Zhang, Hua-Xiang Xu, Zhao-Chong Zeng, Wei-Zhong Wu, Lu Wang, Zhao-You Tang
Intercalative pyrimido[4′,5′:4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution
M. S. Shahabuddin, Mridula Nambiar, Gopal M. Advirao, Sathees C. Raghavan
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity
In Hae Park, Jin Young Kim, Ji Young Choi, Ji-Youn Han
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study
Raphaël Beck, Rozangela Curi Pedrosa, Nicolas Dejeans, Christophe Glorieux, Philippe Levêque, Bernard Gallez, Henryk Taper, Stéphane Eeckhoudt, Laurent Knoops, Pedro Buc Calderon, Julien Verrax
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs
Pamela W. Lucas, Joanna M. Schmit, Quinn P. Peterson, Diana C. West, Danny C. Hsu, Chris J. Novotny, Levent Dirikolu, Mona I. Churchwell, Daniel R. Doerge, Laura D. Garrett, Paul J. Hergenrother, Timothy M. Fan
Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration
Amel Dudakovic, Huaxiang Tong, Raymond J. Hohl
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
Makiko Kobayashi, Ikuko Takahashi-Suzuki, Toshiyasu Shimomura, Yoshikazu Iwasawa, Hiroshi Hirai
Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands
Beatriz Gallego, Milena R. Kaluđerović, Harish Kommera, Reinhard Paschke, Evamarie Hey-Hawkins, Torsten W. Remmerbach, Goran N. Kaluđerović, Santiago Gómez-Ruiz
Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin
Ki-Eun Hwang, Kyoung-Suk Na, Do-Sim Park, Keum-Ha Choi, Byoung-Ryun Kim, Hyeok Shim, Eun-Taik Jeong, Hak-Ryul Kim
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
Neeltje Steeghs, Ron H. J. Mathijssen, Judith A. M. Wessels, Anne-Joy de Graan, Tahar van der Straaten, Mariangela Mariani, Bernard Laffranchi, Silvia Comis, Maja J. A. de Jonge, Hans Gelderblom, Henk-Jan Guchelaar
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer
Donald A. Richards, David Loesch, Svetislava J. Vukelja, Hillary Wu, William J. Hyman, Jeffery Nieves, Yunfei Wang, Simin Hu, Oluwatoyin O. Shonukan, Datchen F. Tai
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
Peter S. Galatin, Ranjana H. Advani, George A. Fisher, Brian Francisco, Thomas Julian, Raquel Losa, Marta I. Sierra, Branimir I. Sikic
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors
Hanna K. Sanoff, Janine M. Davies, Christine Walko, William Irvin, Larry Buie, Kimberly Keller, Anastasia Ivanova, Wing-Keung Chiu, Bert H. O’Neil, Thomas E. Stinchcombe, E. Claire Dees
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
Elena Soto, Ron J. Keizer, Iñaki F. Trocóniz, Alwin D. R. Huitema, Jos H. Beijnen, Jan H. M. Schellens, Jantien Wanders, Josep María Cendrós, Rosendo Obach, Concepción Peraire, Lena E. Friberg, Mats O. Karlsson
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
Benoit You, Anthony Brade, Joao M. Magalhaes, Lillian L. Siu, Amit Oza, Sonya Lovell, Lisa Wang, David W. Hedley, Leonardo V. Nicacio, Eric X. Chen
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Mark Andrew Dickson, Dana E. Rathkopf, Richard D. Carvajal, Steven Grant, John D. Roberts, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Robert A. Lefkowitz, Mithat Gonen, Lauren M. Cane, Heather J. Dials, Gary K. Schwartz
A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials
Som D. Mukherjee, Megan E. Coombes, Mitch Levine, Jarold Cosby, Brenda Kowaleski, Andrew Arnold
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Jaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, Katalin Boer, Antoine Adenis, Pilar Escudero, Tae-You Kim, Gillian M. Pover, Clive D. Morris, Jean-Yves Douillard
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
Juan W. Valle, Anne Armstrong, Chris Newman, Valery Alakhov, Grzegorz Pietrzynski, Julie Brewer, Sue Campbell, Pippa Corrie, Eric K. Rowinsky, Malcolm Ranson
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
José María Viéitez, Manuel Valladares, Ignacio Peláez, Luis de Sande González, Jesús García-Foncillas, José Luis García-López, Carlos García-Girón, Margarita Reboredo, Humberto Bovio, Angel Jiménez Lacave
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
Srikala S. Sridhar, Eric Winquist, Andrea Eisen, Sebastien J. Hotte, Elaine McWhirter, Ian F. Tannock, Som D. Mukherjee, Lisa Wang, Chantale Blattler, John J. Wright, Malcolm J. Moore
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer
Sung Yong Oh, Young-Tae Ju, Sang-Kyung Choi, Chang Yoon Ha, Won Sup Lee, Hoon Gu Kim, Gyeong-Won Lee, Hyuk-Chan Kwon, Jung Hun Kang
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Colin D. Weekes, Sujatha Nallapareddy, Michelle A. Rudek, Alexis Norris-Kirby, Daniel Laheru, Antonio Jimeno, Ross C. Donehower, Kathleen M. Murphy, Manuel Hidalgo, Sharyn D. Baker, Wells A. Messersmith
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness
Sung Yong Oh, Chi Young Jeong, Soon Chan Hong, Tae Hyo Kim, Chang Yoon Ha, Hyun Jin Kim, Gyeong-Won Lee, In Gyu Hwang, Joung Soon Jang, Hyuk-Chan Kwon, Jung Hun Kang
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer
Sang Joon Shin, Jae Heon Jeong, Young Suk Park, Kyung Hee Lee, Byoung Yong Shim, Tae Won Kim, Do Youn Oh, Myung Ah Lee, Yong Tai Kim, Yeul Hong Kim, Dae Young Zang, Jae Kyung Roh, Joong Bae Ahn
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer
Achillia Lakka, Ilias Mylonis, Sophia Bonanou, George Simos, Andreas Tsakalof
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Romain Coriat, Stanislas Ropert, Olivier Mir, Bertrand Billemont, Stanislas Chaussade, Pierre-Philippe Massault, Benoit Blanchet, Olivier Vignaux, François Goldwasser
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model
Stefan Faderl, Carlos Bueso-Ramos, Zhiming Liu, Ashutosh Pal, William Bornmann, Diana V. Ciurea, David Harris, Inbal Hazan-Halevy, Hagop M. Kantarjian, Zeev Estrov
Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
Moon Jin Kim, Gyeong-Won Lee, Jong Woo Seo, Hyun-Jung Kim, Sung-Nam Lim, Cheolwon Suh
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide
Catherine J. Drummond, Graeme J. Finlay, Laura Broome, Elaine S. Marshall, Emma Richardson, Bruce C. Baguley
Ultraviolet recall dermatitis reaction with sorafenib
Nicolas Magné, Cyrus Chargari, Pierre Auberdiac, Coralie Moncharmont, Yacine Merrouche, Jean-Philippe Spano
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
Yevgeniy Balagula, Katherine Barth Huston, Klaus J. Busam, Mario E. Lacouture, Paul B. Chapman, Patricia L. Myskowski
Erratum to: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs
Joseph A. Bauer, Gerald Frye, Anne Bahr, Jennifer Gieg, Peter Brofman